Amazon Offers Hope As US Pricing Approaches ‘Pain Point’ For Manufacturers, Says Lupin
Executive Summary
Pricing pressure in the US continued to hurt Lupin, denting its Q2 earnings, with the company’s management suggesting that manufacturers, both US and Indian, could be nearing their “pain point”. CEO Vinita Gupta also maintained that a potential entry of Amazon into the pharmacy business could be “real positive” for the generic industry.
You may also be interested in...
Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge
After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.
Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge
After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.